SR One names Jens Eckstein president
This article was originally published in Scrip
Jens Eckstein has been named president of SR One, GSK's independent healthcare venture organisation, effective 1 October. Mr Eckstein will replace Christoph Westphal who is leaving GSK at the end of the year to focus on external business interests, including the Longwood Founder's Fund in which GSK is an investor. Mr Eckstein has served at TVM Capital since 2004, currently as venture partner and entrepreneur-in-residence. He is also currently interim CEO and president of SelectX Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.